Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
Abstract Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have been used in clinic settings to treat cancer. They have also recently been applied to antibody–drug conjugates (ADCs); however, their clinical efficacy is limited by severa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-15838-8 |
| _version_ | 1818519303283015680 |
|---|---|
| author | Jun-ichiro Takahashi Shiori Nakamura Iimi Onuma Yue Zhou Satoru Yokoyama Hiroaki Sakurai |
| author_facet | Jun-ichiro Takahashi Shiori Nakamura Iimi Onuma Yue Zhou Satoru Yokoyama Hiroaki Sakurai |
| author_sort | Jun-ichiro Takahashi |
| collection | DOAJ |
| description | Abstract Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have been used in clinic settings to treat cancer. They have also recently been applied to antibody–drug conjugates (ADCs); however, their clinical efficacy is limited by several issues, including lower internalization efficiency. The binding of cetuximab to the extracellular domain of EGFR suppresses ligand-induced events; therefore, we focus on ligand-independent non-canonical EGFR endocytosis for the delivery of ADCs into cells. Tumor necrosis factor-α (TNF-α) strongly induces the endocytosis of the cetuximab-EGFR complex within 15 min via the p38 phosphorylation of EGFR in a tyrosine kinase-independent manner. A secondary antibody conjugated with saporin, a ribosome-inactivating protein, also undergoes internalization with the complex and enhances its anti-proliferative activity. Anti-cancer agents, including cisplatin and temozolomide, also induce the p38-mediated internalization. The results of the present study demonstrate that synchronous non-canonical EGFR endocytosis may be a feasible strategy for promoting the therapeutic efficacy of EGFR-targeting ADCs in clinical settings. |
| first_indexed | 2024-12-11T01:22:22Z |
| format | Article |
| id | doaj.art-c648e60397b34db2bab19b9a6dd2767a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-11T01:22:22Z |
| publishDate | 2022-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-c648e60397b34db2bab19b9a6dd2767a2022-12-22T01:25:40ZengNature PortfolioScientific Reports2045-23222022-07-0112111210.1038/s41598-022-15838-8Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosisJun-ichiro Takahashi0Shiori Nakamura1Iimi Onuma2Yue Zhou3Satoru Yokoyama4Hiroaki Sakurai5Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of ToyamaAbstract Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have been used in clinic settings to treat cancer. They have also recently been applied to antibody–drug conjugates (ADCs); however, their clinical efficacy is limited by several issues, including lower internalization efficiency. The binding of cetuximab to the extracellular domain of EGFR suppresses ligand-induced events; therefore, we focus on ligand-independent non-canonical EGFR endocytosis for the delivery of ADCs into cells. Tumor necrosis factor-α (TNF-α) strongly induces the endocytosis of the cetuximab-EGFR complex within 15 min via the p38 phosphorylation of EGFR in a tyrosine kinase-independent manner. A secondary antibody conjugated with saporin, a ribosome-inactivating protein, also undergoes internalization with the complex and enhances its anti-proliferative activity. Anti-cancer agents, including cisplatin and temozolomide, also induce the p38-mediated internalization. The results of the present study demonstrate that synchronous non-canonical EGFR endocytosis may be a feasible strategy for promoting the therapeutic efficacy of EGFR-targeting ADCs in clinical settings.https://doi.org/10.1038/s41598-022-15838-8 |
| spellingShingle | Jun-ichiro Takahashi Shiori Nakamura Iimi Onuma Yue Zhou Satoru Yokoyama Hiroaki Sakurai Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis Scientific Reports |
| title | Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis |
| title_full | Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis |
| title_fullStr | Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis |
| title_full_unstemmed | Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis |
| title_short | Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis |
| title_sort | synchronous intracellular delivery of egfr targeted antibody drug conjugates by p38 mediated non canonical endocytosis |
| url | https://doi.org/10.1038/s41598-022-15838-8 |
| work_keys_str_mv | AT junichirotakahashi synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis AT shiorinakamura synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis AT iimionuma synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis AT yuezhou synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis AT satoruyokoyama synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis AT hiroakisakurai synchronousintracellulardeliveryofegfrtargetedantibodydrugconjugatesbyp38mediatednoncanonicalendocytosis |